Prolactin receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in acute myeloid leukemia

Cuesta-Casanovas, Laia; Delgado-Martínez, Jennifer; Cornet-Masana, Josep M.; Carbó, José M.; Banús-Mulet, Antònia; Guijarro, Francesca; Esteve, Jordi; Risueño, Ruth M.

doi:10.1186/s12935-023-02944-4

Table 1 AML patients’ information

From: Prolactin receptor signaling induces acquisition of chemoresistance and reduces clonogenicity in acute myeloid leukemia

AML	Type	Sex	Age	WHO subtype	BPB (%)	BBM (%)	Karyotype	Additional molecular features	Risk	CR
#1	BM	M	49	Therapy related AML	42	26	46–47, XY, del(5)(q22q34),del(6)(q22q25),del(7)(q22q23),-8,-9,add(11)(q23),+i(11)(q11),-16,+mar1,+mar2,+mar3[cp8]	None	Adv	Yes
#2	PB	M	64	AML without maturation	1	35	46,XY[20]	None	Int	No
#3	N/D	F	45	AML treatment-related	22	44	46,XX[20]	None	Int	No
#4	PB	F	51	AML with mutated NPM1	26	63	N/D	NPM1 mut	Fav	No
#5	N/D	M	61	AML with mutated NPM1	33	72	46,XY[20]	NPM1 mut, DNMT3A mut	Fav	Yes
#6	N/D	M	51	AML with myelodysplasia-related changes	88	93	46,XY,-5,+mar1[4]/46,XY,-5,+mar2[4]	None	Adv	Yes
#7	N/D	F	54	AML with myelodysplasia-related changes	47	83	48,XX,+add(13)(q34),+add(13)(q34)[8]/46,XX[5]	None	Int	Yes
#8	LA	F	44	AML with mutated NPM1	76	80	N/D	NPM1 mut	Fav	No
#9	LA	F	67	MPAL, T/Myeloid, NOS	53	30	46,XX[21]	None	Int	Yes
#10	PB	F	80	AML with mutated NPM1	53	95	46,XX[20]	FLT3-ITD, NPM1 mut	Int	No
#11	BM	M	41	AML with t(3;3)(q21.3;q26.2); GATA2. MECOM	57	73	46,XY,t(3;3)(q21;q26)[1]/45,X,-Y,t(3;3)(q21;q26)[19]	None	Adv	Yes
#12	BM	M	45	N/D	N/D	0	46,XY[20]	FLT3-ITD	Adv	No
#13	BM	M	71	AML with mutated NPM1	0	3	Normal	NPM1 mut	Fav	No
#14	BM	M	27	N/D	0	2	46,XY[20]	None	Int	No
#15	BM	M	27	AML with myelodysplasia-related changes	3	34	46,XY[37]	FLT3-ITD	Int	No
#16	PB	M	69	AML with myelodysplasia-related changes	23	3	43,XY,-4,add(4)(q?35),del(5)(q13q33),-7,der(12)t(12;?14)(p?12;q?12),-14,-15,del(20)(q11q13),-21,+mar1,+mar2[22]	None	Adv	N/D
#17	BM	F	45	AML with myelodysplasia-related changes	0	20	46,XX[20]	None	Int	No
#18	BM	F	82	AML with mutated NPM1	79	83	46,XX,der(12)t(1;12)(q21;q24.3)[4]/46,XX[12]	NPM1 mut	Fav	Yes
#19	BM	M	78	N/D	0	0	Normal	None	Int	No
#20	BM	M	73	N/D	0	27	Complex	None	Adv	No
#21	BM	M	70	N/D	0	5	46,XY[20]	None	Int	No
#22	BM	M	78	N/D	0	0	Normal	None	Int	No
#23	BM	M	27	N/D	0	6	46,XY[20]	None	Int	No
#24	BM	M	47	APL with PML-RARA	71	0	46,XY[20]	N/D	Fav	No
#25	BM	M	71	AML with mutated NPM1	N/D	0	Normal	NPM1 mut	Fav	No
#26	BM	M	68	AML with myelodysplasia-related changes	N/D	N/D	N/D	N/D	N/D	N/D
#27	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D
#28	PB	M	75	N/D	N/D	98	46,XY,inv(3)(p25q21),del(11)(p11.1p15)[cp14]	None	N/D	N/D
#29	BM	M	64	AML with mutated NPM1	56	78	46,XY[20]	NPM1 mut	Fav	No
#30	PB	F	47	AML with inv(3)(q21.3q26.2); GATA2, MECOM	3	23	46,XX,inv(3)(q21q26.2)[17]/46,XX[30]	None	Adv	Yes
#31	BM	F	90	AML with myelodysplasia-related changes	92	77	42,XX,del(5)(q22q34),del(7)(q22q32),add(8)(q24),-15,-16,add(17)(p13),-18,-19,-20,-21,-22,-22,+r(?),+mar[cp18]*	TP53 mut	Adv	N/D
#32	PB	F	90	AML with myelodysplasia-related changes	92	77	42,XX,del(5)(q22q34),del(7)(q22q32),add(8)(q24),-15,-16,add(17)(p13),-18,-19,-20,-21,-22,-22,+r(?),+mar[cp18]*	TP53 mut	Adv	N/D
#33	LA	F	63	AML with mutated NPM1	100	94	N/D	FLT3-ITD, DNMT3A mut, IDH2mut	Int	No
#34	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D
#35	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D
#36	PB	F	64	AML without differentiation	48	73	46,XX[30]	MLL-PTD, IDH2 mut, DNMT3A mut	Adv	No
#37	PB	F	69	AML with mutated NPM1	68	66	47,XX,+8[20]	NRAS mut, RUNX1 mut, CEBPA mut	Adv	No
#38	BM	M	62	AML with inv(3)(q21.3q26.2); GATA2, MECOM	18	61	46,XY,inv(3)(q21q26.2)[8]/46,XY[20]	DNMT3A mut, IDH1 mut	Adv	No
#39	PB	F	77	AML with mutated NPM1	95	85	N/D	FLT3-ITD, TET2 mut	Int	N/D
#40	PB	M	62	AML with mutated RUNX1	49	81	6,XY,del(7)(?)[19]/46,XY[1]	None	Adv	No
#41	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D		N/D
#42	PB	M	63	AML with myelodysplasia-related changes	43	30	N/D	TP53 mut	Adv	Yes
#43	BM	M	27	N/D	0	1	46,XY[20]	BCR/ABL absence	Int	No
#44	BM	M	57	N/D	43	33	46,XY[5]	None	Int	No
#45	BM	M	71	AML with mutated NPM1	N/D	1	Normal	NPM1 mut	Fav	No
#46	BM	M	73	N/D	0	27	Complex	None	Adv	No
#47	BM	M	43	N/D	29	6	46,XY[30]	None	Int	Yes
#48	BM	M	78	AML with myelodysplasia-related changes	0	N/D	N/D	N/D	N/D	N/D
#49	LA	M	47	AML with mutated NPM1	23	48	Normal	DNMT3A mut, IDH2 mut, TP53 mut	Adv	No
#50	LA	M	40	AML with mutated NPM1	96	93	N/D	IDH1 mut, NPM1 mut, FLT3-ITD	Adv	N/D
#51	LA	M	37	AML with inv(16)(p13.1q22); CBFB-MYH11	98	91	47,XY,+9,inv(16)(p13;q22),der(17)t(11;17)(q13;q25)[10]	CEPBA mut, FLT3 mut, WT1 mut	Fav	No
#52	LA	F	21	AML NOS, monoblastic	98	98	46,XX,t(1;20;11')(p36q21;q11.2;q23),t(10;inv(11)(q13q23))(p12;q13)[20]	KMT2A rearrangement	Adv	No
#53	LA	M	65	AML with mutated NPM1	62	80	46,XY[20]	NPM1 mut, FLT3-ITD	Fav	No
#54	PB	M	71	AML with mutated NPM1	86	84	N/D	NPM1 mut, FLT3-ITD	Int	N/D
#55	PB	M	55	AML with mutated NPM1	85	76	46,XY[20]	NPM1 mut, IDH1 mut, DNMT3A mut, TET2 mut, PTPN11 mut	Fav	N/D
#56	PB	F	68	AML with mutated NPM1	54	66	46,XY[20]	NPM1 mut, DNMT3A mut, FLT3-TKD, IDH1 mut, NRAS mut	Fav	No
#57	PB + BM	F	74	AML with biallelic mutation of CEBPA	20	23	46,XX[20]	CEBPA, TET2	Fav	No
#58	PB	F	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D
#59	PB	M	84	AML with myelodysplasia-related changes	84	66	46,XY,del(20)(q11q13)[5]/48,XY,+8,del(20)(q11q13),+21[15]	JAK2 mut, IDH2 mut, SRSF2 mut, ETV6-MN1 rearrangement	Int	N/D
#60	PB + BM	M	72	AML with mutated NPM1	16	38	46,XY[20]	NPM1 mut, FLT3-ITD, IDH2 mut, RUNX1 mut, WT1 mut, IDH1 mut, DNMT3A mut	Fav	N/D
#61	LA	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D	N/D

AML patients’ information
Age in years; Adv adverse, AML acute myeloid leukemia, BBM blasts in bone marrow, BM bone marrow, BPM blasts in peripheral blood, CR chemoresistance, F female, Fav favorable, Int intermediate, M male, N/D not determined, PB peripheral blood, Risk cytogenetic risk group according to 2017 ELN recommendations [53], WHO subtype WHO subtype according with the 2016 WHO classification [15]

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Cell International

Contact us